Media stories about Intercept Pharmaceuticals (NASDAQ:ICPT) have been trending somewhat positive this week, Accern Sentiment reports. The research firm identifies positive and negative press coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Intercept Pharmaceuticals earned a news impact score of 0.24 on Accern’s scale. Accern also gave news articles about the biopharmaceutical company an impact score of 45.3203754338786 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
Here are some of the media stories that may have impacted Accern Sentiment’s analysis:
- Intercept Pharmaceuticals Becomes Oversold (ICPT) – Nasdaq (nasdaq.com)
- Investor Watch: Checking on Shares of Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) – Jonesboro Recorder (jonesbororecorder.com)
- Corporate News Blog – FDA Grants Orphan Drug Designation to Omeros’ OMS721 for Treatment of IgA Nephropathy (finance.yahoo.com)
- Cantor Fitzgerald Reiterates “Underweight” Rating for Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) (americanbankingnews.com)
Shares of Intercept Pharmaceuticals (ICPT) traded up 2.05% during mid-day trading on Friday, hitting $103.19. The stock had a trading volume of 343,264 shares. Intercept Pharmaceuticals has a 1-year low of $96.63 and a 1-year high of $172.95. The stock’s 50-day moving average is $120.81 and its 200-day moving average is $117.78. The firm’s market capitalization is $2.59 billion.
Intercept Pharmaceuticals (NASDAQ:ICPT) last announced its quarterly earnings results on Monday, July 31st. The biopharmaceutical company reported ($3.46) EPS for the quarter, beating the Zacks’ consensus estimate of ($3.62) by $0.16. The firm had revenue of $30.89 million for the quarter, compared to analyst estimates of $27.50 million. Intercept Pharmaceuticals had a negative return on equity of 135.24% and a negative net margin of 543.35%. The business’s revenue for the quarter was up 459.6% on a year-over-year basis. During the same period last year, the firm posted ($3.14) earnings per share. Equities analysts expect that Intercept Pharmaceuticals will post ($14.05) earnings per share for the current year.
Several research analysts recently issued reports on ICPT shares. Cowen and Company reiterated a “buy” rating and set a $225.00 price target on shares of Intercept Pharmaceuticals in a research report on Monday, April 24th. Credit Suisse Group set a $201.00 price target on shares of Intercept Pharmaceuticals and gave the stock a “buy” rating in a research report on Saturday, June 3rd. Oppenheimer Holdings, Inc. set a $200.00 price target on shares of Intercept Pharmaceuticals and gave the stock a “buy” rating in a research report on Thursday, May 4th. BidaskClub upgraded shares of Intercept Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Friday, June 23rd. Finally, Jefferies Group LLC started coverage on shares of Intercept Pharmaceuticals in a research report on Monday, July 10th. They set a “buy” rating and a $275.00 price target on the stock. Two analysts have rated the stock with a sell rating, five have assigned a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the company’s stock. Intercept Pharmaceuticals has a consensus rating of “Buy” and a consensus price target of $203.67.
ILLEGAL ACTIVITY NOTICE: “Somewhat Positive News Coverage Somewhat Unlikely to Impact Intercept Pharmaceuticals (ICPT) Stock Price” was first published by StockNewsTimes and is the sole property of of StockNewsTimes. If you are accessing this piece of content on another site, it was copied illegally and reposted in violation of US and international copyright and trademark law. The original version of this piece of content can be viewed at https://stocknewstimes.com/2017/08/12/somewhat-positive-news-coverage-somewhat-unlikely-to-impact-intercept-pharmaceuticals-icpt-stock-price.html.
In related news, Director Daniel G. Welch sold 602 shares of Intercept Pharmaceuticals stock in a transaction that occurred on Monday, July 31st. The stock was sold at an average price of $123.93, for a total value of $74,605.86. Following the transaction, the director now directly owns 3,108 shares of the company’s stock, valued at $385,174.44. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Lisa Bright sold 698 shares of Intercept Pharmaceuticals stock in a transaction that occurred on Thursday, June 1st. The stock was sold at an average price of $110.73, for a total value of $77,289.54. Following the completion of the transaction, the insider now directly owns 24,711 shares in the company, valued at $2,736,249.03. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 47,575 shares of company stock worth $6,144,469. 9.20% of the stock is owned by insiders.
Intercept Pharmaceuticals Company Profile
Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.
Receive News & Ratings for Intercept Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.